Proto-Oncogene Proteins B-raf
"Proto-Oncogene Proteins B-raf" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A raf kinase subclass found at high levels in neuronal tissue. The B-raf Kinases are MAP kinase kinase kinases that have specificity for MAP KINASE KINASE 1 and MAP KINASE KINASE 2.
Descriptor ID |
D048493
|
MeSH Number(s) |
D08.811.913.696.620.682.700.559.842.374 D12.644.360.400.842.374 D12.776.476.400.842.437 D12.776.624.664.700.204.200
|
Concept/Terms |
Proto-Oncogene Proteins B-raf- Proto-Oncogene Proteins B-raf
- B-raf, Proto-Oncogene Proteins
- Proteins B-raf, Proto-Oncogene
- Proto Oncogene Proteins B raf
- BRAF Kinases
- B-raf Kinases
- B raf Kinases
- Proto-Oncogene Protein B-raf
- B-raf, Proto-Oncogene Protein
- Protein B-raf, Proto-Oncogene
- Proto Oncogene Protein B raf
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins B-raf".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins B-raf".
This graph shows the total number of publications written about "Proto-Oncogene Proteins B-raf" by people in this website by year, and whether "Proto-Oncogene Proteins B-raf" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2002 | 0 | 4 | 4 |
2004 | 2 | 2 | 4 |
2005 | 2 | 1 | 3 |
2006 | 4 | 2 | 6 |
2007 | 3 | 2 | 5 |
2008 | 2 | 7 | 9 |
2009 | 6 | 8 | 14 |
2010 | 7 | 5 | 12 |
2011 | 9 | 9 | 18 |
2012 | 20 | 12 | 32 |
2013 | 17 | 19 | 36 |
2014 | 31 | 18 | 49 |
2015 | 32 | 26 | 58 |
2016 | 21 | 15 | 36 |
2017 | 28 | 20 | 48 |
2018 | 17 | 10 | 27 |
2019 | 13 | 16 | 29 |
2020 | 16 | 14 | 30 |
2021 | 15 | 10 | 25 |
2022 | 5 | 24 | 29 |
2023 | 4 | 20 | 24 |
2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogene Proteins B-raf" by people in Profiles.
-
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial. Nat Commun. 2024 Mar 19; 15(1):2446.
-
Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid. 2024 Mar; 34(3):336-346.
-
Targeting All BRAF Alterations: The (Re)-Search Continues. JCO Precis Oncol. 2024 Feb; 8:e2300670.
-
Circulating senescent myeloid cells infiltrate the brain and cause neurodegeneration in histiocytic disorders. Immunity. 2023 Dec 12; 56(12):2790-2802.e6.
-
Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer. JAMA Netw Open. 2023 Dec 01; 6(12):e2347700.
-
Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers. Clin Cancer Res. 2023 12 01; 29(23):4853-4862.
-
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. Nat Med. 2024 Jan; 30(1):207-217.
-
Convergent MAPK pathway alterations mediate acquired?resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma. J Hepatol. 2024 Feb; 80(2):322-334.
-
Conditional Overall Survival After Diagnosis of Non-Metastatic Colon Cancer: Impact of Laterality, MSI, and KRAS Status. Ann Surg Oncol. 2024 Jan; 31(1):142-151.
-
BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors. Oncologist. 2023 09 07; 28(9):771-779.